You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
25
Nov 24
Analysts’ Conference
28
Press Release – quarterly statement (call-date Q3)
13
Aug 24
Publication half-yearly financial statements
12
Jun 24
Annual General Meeting
May 24
08
Press Release – quarterly financial report (call-date Q1)
Apr 24
Publication of Annual Report
27
Nov 23
Press Release – quarterly financial report (call-date Q3)
30
Aug 23
Jul 23
May 23
15
Apr 23
Nov 22
Nov
2022
Oct 22
Jun 22
21
Press Release – quarterly statement (call-date Q1)
23
May 22
18
09
Nov 21
Publication quarterly statement (call-date Q3)
Sep 21
Jun 21
Publication quarterly statement (call-date Q1)
17
May 21
10
Dec 20
16
Nov 20
11
Sep 20
22
Jun 20
May 20
Mar 20
Sep
2019
Jun 19
May 19
2018
19
Jun 18
Jun
2017
Jun 17
19 November 2024
Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
18 November 2024
Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
15 November 2024
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
13 November 2024
22 October 2024
Half-yearly financial statements 2024
29 April 2024
Annual financial statements 2023
30 August 2023
Half-yearly financial statements 2023
1 October 2024
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
19 August 2024
13 June 2024
21 August 2023
23 September 2022
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Kaufen
7 September 2022